SOM Biotech Licenses its First Product and Expands to the United States

Tuesday, July 25, 2017 Medico Legal News
Email Print This Page Comment bookmark
Font : A-A+

- SOM's has granted a worldwide exclusive license to Corino Therapeutics Inc. following clinical Phase 2 testing of its lead compound SOM0266 for the treatment of TTR Amyloidosis.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook